Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Hospital Authority, Hong Kong
With
Baxter Healthcare Corporation
Age
50–80
Sex
MALE
Healthy volunteers
Not accepted
You may be eligible if
Prostate cancer patients aged between 50-80 who is having or will have ADT. Baseline BMD in between -2 standard deviation (SD) and mean of that among young adults.
You may not be if
Patients with renal or liver problems, on calcium or other bisphosphonate therapy within six months before enrolling into the study.
Patients who have:
Serum creatinine levels \>212 µmol/L (2.4 mg/dL).
Creatinine clearance \<50 ml/min.
WBC \<4.0x109/L, Hgb \<10 g/dL, platelets \<140x109/L. Patients with known hypersensitivity to bisphosphonates. Patients with history of diseases with influence on bone metabolism, such as Page's disease of bone, primary hyperparathyroidism or osteoporosis.
Clareo Health | Study on Evaluation of Zoledronic Acid to Prevent Bone Loss in Men Receiving Androgen Deprivation Therapy for Prostate Cancer
